HMG
Also known as · Human menopausal gonadotropin · Menotropins · Menopur · Repronex
- EvidenceApproved
- CategoryGonadotropin
- RoutesubQ / IM
- Half-lifeFSH ~34 h · LH ~10–12 h
01 / Dosing schedule
Cited dosing
The FDA-approved Menopur schedule uses a 225 IU/day initial subcutaneous dose in women who have received a GnRH agonist for pituitary suppression, adjusted based on follicular response.
Menopur — ART cycle with GnRH suppression
| Phase | Dose & frequency |
|---|---|
| Initial dose | 225 IU subQ once daily |
| Adjustment | By follicular response (ultrasound + serum estradiol) |
| Typical duration | Do not exceed 12 days per cycle |
| Maximum combined daily dose | 450 IU (Menopur + Bravelle) |
| Vial contents | 75 IU FSH activity + 75 IU LH activity per vial |
Source · FDA label — Menopur (2014) ↗
Source indication · Development of multiple follicles in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle (Menopur label).
- Injection frequency
- Once daily during the follicular-development phase of an ART cycle.
- Injection sites
- Lower abdomen, 1–2 inches below the navel. Alternate sides daily.
02 / Reconstitution
Reconstitution reference
Each vial contains 75 IU FSH + 75 IU LH activity as lyophilized powder, reconstituted with 0.9% sodium chloride injection using the supplied Q•Cap device. For a 225 IU dose, three vials are typically pooled into one syringe.
03 / Overview
Protocol overview
Menotropins are purified urinary gonadotropins containing FSH and LH activity in a roughly 1:1 ratio. They act directly on ovarian follicles to drive multi-follicular development in ART.
The FDA-approved indication is ovulation induction and controlled ovarian stimulation in women undergoing assisted reproductive technology cycles. It is not FDA-approved for male fertility.
The label emphasizes response-guided dosing — daily monitoring with ultrasound and serum estradiol — rather than fixed titration. Overshoot risks ovarian hyperstimulation syndrome.
The 225 IU starting dose applies specifically to women pre-treated with a GnRH agonist. Different protocols apply outside ART.
04 / References